
Assoc. Professor in Residence
Primary Thematic Area
M_MED-CORE-HMON-ONCO-GEN
Secondary Thematic Area
Research Summary
The Okimoto lab aims to understand how transcriptional dysregulation leads to cancer growth and metastasis.
The Okimoto lab aims to understand how transcriptional dysregulation leads to cancer growth and metastasis. We use in vivo model systems to study the functional output of perturbed molecular networks and seek to develop new therapies to target transcriptional dependence in cancer.
Publications
First Generation Tools for the Modeling of Capicua (CIC) - Family Fusion Oncoprotein-Driven Cancers.
bioRxiv : the preprint server for biology
The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein.
Cancer research communications
A Platform to Deliver Single and Bi-specific Cas9/guide RNA to Perturb Genes in Vitro and in Vivo.
Molecular therapy : the journal of the American Society of Gene Therapy
The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein.
bioRxiv : the preprint server for biology
Molecular and therapeutic advancements in Capicua (CIC)-rearranged sarcoma.
Frontiers in cell and developmental biology
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.
NPJ precision oncology
Mapping chromatin state and transcriptional response in CIC-DUX4 undifferentiated round cell sarcoma.
bioRxiv : the preprint server for biology
Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer.
Cell reports
Primary and metastatic tumors exhibit systems-level differences in dependence on mitochondrial respiratory function.
PLoS biology
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer.
The Journal of clinical investigation
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.
Nature communications
Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma.
Cancer immunology, immunotherapy : CII
Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.
Science (New York, N.Y.)
Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis.
Oncogenesis
Capicua in Human Cancer.
Trends in cancer
Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma.
Proceedings of the National Academy of Sciences of the United States of America
CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.
The Journal of clinical investigation
Metastasis: From head to tail.
Cell cycle (Georgetown, Tex.)
Inactivation of Capicua drives cancer metastasis.
Nature genetics
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Proceedings of the National Academy of Sciences of the United States of America
Tracking Down Response and Resistance to TRK Inhibitors.
Cancer discovery
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Nature medicine
AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Lung Cancer (Auckland, N.Z.)
Prednisolone-induced predisposition to femoral head separation and the accompanying plasma protein changes in chickens.
Biomarker insights
77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL).
Brain pathology (Zurich, Switzerland)
Recent advances in personalized lung cancer medicine.
Personalized medicine
Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
Current opinion in hematology
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Cancer research
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.
Proceedings of the National Academy of Sciences of the United States of America
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
Clinical cancer research : an official journal of the American Association for Cancer Research
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
Nature genetics
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Proceedings of the National Academy of Sciences of the United States of America
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
The New England journal of medicine